Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Lexaria Bioscience Corp (LXX.CN)

Lexaria Bioscience Corp (LXX.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 42,270
  • Shares Outstanding, K 5,104
  • Annual Sales, $ 723 K
  • Annual Income, $ -4,027 K
  • 60-Month Beta 1.81
  • Price/Sales 28.56
  • Price/Cash Flow N/A
  • Price/Book 2.99
Trade LXX.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.86
  • Most Recent Earnings 0.09 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.620 +10.24%
on 06/10/21
9.010 -6.77%
on 06/28/21
-0.140 (-1.64%)
since 06/08/21
3-Month
5.800 +44.83%
on 04/20/21
10.610 -20.83%
on 05/06/21
+1.520 (+22.09%)
since 04/08/21
52-Week
5.100 +64.71%
on 01/12/21
20.700 -59.42%
on 07/20/20
-2.250 (-21.13%)
since 07/08/20

Most Recent Stories

More News
Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment

NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making...

LXRP : 0.2249 (-10.68%)
LXX.CN : 8.400 (-1.18%)
LEXX : 2.76 (-7.38%)
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...

LXRP : 0.2249 (-10.68%)
LXX.CN : 8.400 (-1.18%)
LEXX : 2.76 (-7.38%)
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation

NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers...

LXRP : 0.2249 (-10.68%)
LXX.CN : 8.400 (-1.18%)
LEXX : 2.76 (-7.38%)
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment

NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...

LXRP : 0.2249 (-10.68%)
LXX.CN : 8.400 (-1.18%)
LEXX : 2.76 (-7.38%)
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets

KELOWNA, BC / ACCESSWIRE / July 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that...

LEXX : 2.76 (-7.38%)
LEXXW : 0.6999 (-22.22%)
LXX.CN : 8.400 (-1.18%)
Lexaria Announces 2021 Annual Meeting Results

KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results...

LEXX : 2.76 (-7.38%)
LEXXW : 0.6999 (-22.22%)
LXX.CN : 8.400 (-1.18%)
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs

DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW)...

LEXX : 2.76 (-7.38%)
LEXXW : 0.6999 (-22.22%)
LXX.CN : 8.400 (-1.18%)
Lexaria Provides Progress Report on Six R&D Programs

- All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine - These studies are part of Lexaria's 2021 applied...

LEXX : 2.76 (-7.38%)
LEXXW : 0.6999 (-22.22%)
LXX.CN : 8.400 (-1.18%)
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1

- Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria’s Patented Technology for Hypertension Relief - Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation...

LEXX : 2.76 (-7.38%)
LEXXW : 0.6999 (-22.22%)
LXX.CN : 8.400 (-1.18%)
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus

KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that remdesivir...

LEXX : 2.76 (-7.38%)
LEXXW : 0.6999 (-22.22%)
LXX.CN : 8.400 (-1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 8.400
2nd Resistance Point 8.400
1st Resistance Point 8.400
Last Price 8.400
1st Support Level 8.400
2nd Support Level 8.400
3rd Support Level 8.400

See More

52-Week High 20.700
Fibonacci 61.8% 14.741
Fibonacci 50% 12.900
Fibonacci 38.2% 11.059
Last Price 8.400
52-Week Low 5.100

See More

Business Summary

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar